Financial Reports
Related Searches:
Filter by:
April 15, 2009
Worldwide pharmaceutical sales were $3.6 billion (-6%). Humira sales were $1.0 billion (+17%).
Read More »
April 14, 2009
Worldwide pharmaceutical sales were $5.8 billion in the quarter (-10%) with an operational decline of 5% and a negative impact from currency of 5%. Domestic sales were down 10%.
Read More »
March 6, 2009
Operating income was $3.9 million in the quarter, compared to a loss of $4.0 million in 1Q08. Gross profit was up 19% to $30.7 million due to improved cost structure, favorable foreign exchange impact and lower inventory provisions, offsetting lower reven
Read More »
February 25, 2009
Service revenues in the quarter were $109 million (+5%) and $475.1 million for the year (+19%). New business awards totaled $163 million in the quarter and $759 million for the year.
Read More »
February 23, 2009
Business awards for the year were $1.3 billion (+28%) and for the quarter were $261 million.
Read More »
February 19, 2009
Oncaspar sales were $12.1 million in the quarter (+9%) and $50.1 million for the year (+29%). DepoCyt sales were $2.5 million (+24%) and $9.0 million for the year (+5%).
Read More »
February 19, 2009
Service revenue was $6.0 million in the quarter (-25%). Product revenue was $2.0 million (-16%). Loss from continuing operations was $2.0 million.
Read More »
February 17, 2009
In the Americas Pharmaceutical Specialty Injectables sales were $347.2 million in the quarter (-1%) and $1.3 billion for the year (+7%). Other Pharma revenue was $147.6 million in the quarter (-5%) and $522 million for the year (-5%).
Read More »
February 12, 2009
Sales in the quarter were up 1% excluding the impact of foreign exchange. Sales of controlled substances increased due to higher demand, offset by decreases due to delays in certain custom development projects, lower sales of generic APIs, and lower contr
Read More »
February 11, 2009
Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%).
Read More »
February 11, 2009
Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%).
Read More »
February 10, 2009
Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition.
Read More »
February 10, 2009
Preclinical Services (PCS) segment revenue was $158.6 million (-8%) due to slower market demand and the negative impact of foreign exchange.
Read More »
February 9, 2009
Contract revenue for the quarter, which includes Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing, was $49.6 million (+22%) and $195.5 million for the year (+20%).
Read More »
February 6, 2009
Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year.
Read More »
